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In Vitro Reconstitution of Human B-Cell Ontogeny:
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By Anne-Catherine Fluckiger, Eva Sanz, Maria Garcia-Lloret, Thomas Su, Qian-Lin Hao, Roberta Kato,
Shirley Quan, Antonio de la Hera, Gay M. Crooks, Owen N. Witte, and David J. Rawlings
We describe a long-term, in vitro culture system initiated
with CD341 or CD341CD382 umbilical cord blood hematopoi-
etic progenitors that supports normal human B-lineage
development, including the production of mature Ig-secret-
ing B cells. In the first stage (human B-progenitor long-term
culture [HB-LTC]), CD341 hematopoietic progenitors are cul-
tured on the murine stromal cell line, S17, leading to the
sustained production of large numbers of CD101, CD191
early B progenitors. Reverse transcriptase-polymerase chain
reaction (RT-PCR) and three-parameter flow cytometry for
VpreB (surrogate light chain), cytoplasmic m chain, and
surface IgM expression were used to characterize the CD191
B progenitors present within these cultures. This analysis
showed distinct B-lineage subpopulations, including pro-B
cells, cycling pre-B cells, and IgM1, IgD2/1 immature B cells.
The limited expansion of IgM1 B cells and the immature
surface phenotype of this population (IgM1, IgD1, CD101,
CD381) suggested that HB-LTC conditions were unable to
provide appropriate signals for further differentiation. A
second culture stage was used to determine if these imma-
ture B cells were functionally competent. Purified CD191
cells were transferred onto fibroblasts expressing human
CD40-ligand in the presence of IL-10 and IL-4. This lead to cell
proliferation, modulation of the IgM1 cell surface phenotype
to one consistent with an activated mature B cell, secretion
of Ig, and isotype switching. Notably, IgM and IgG producing
B cells were also generated using two-stage cultures estab-
lished with highly purified multipotent CD341CD382 hemato-
poietic stem cell progenitors. This culture model should
permit detailed in vitro analysis and genetic manipulation of
the major transition points in human B ontogeny, beginning
with commitment to the B lineage and leading to develop-
ment and activation of mature B cells.
r 1998 by The American Society of Hematology.
B LYMPHOPOIESIS is a developmentally regulated pro-cess characterized by expression of specific regulatory
genes, cell surface molecules, and somatic gene rearrangements
leading ultimately to production of Ig-secreting plasma B cells.
These events are controlled through cell-cell interactions, by
hematopoietic growth factors, and by signaling through the
pre-B– and B-cell antigen receptors. These receptors regulate
two key steps during B-lineage development: (1) the pre-B to
immature B cell and (2) the naive to activated B-cell transi-
tions.1-5 Pre-B– and B-cell antigen receptor-dependent signals
are essential for Ig chain allelic exclusion and proliferation of
bone marrow pre-B cells and for activation and proliferation of
naive B cells after encounter with antigen in the peripheral
lymphoid tissues. The timing, dosage, and cellular microenviron-
mental context of antigen receptor engagement further modu-
lates these events. Dysregulation of these signals can lead,
alternatively, to humoral immunodeficiencies or to autoimmu-
nity or malignancy.6-8
The complexity of mammalian bone marrow and lymphoid
tissues has impeded detailed in vivo molecular and phenotypic
analysis of events regulating both primary (bone marrow-
dependent) and secondary (peripheral lymphoid tissue-depen-
dent) B-lineage development. Analysis of normal and altered
human B lymphopoiesis must rely primarily on in vitro or
SCID/Hu in vivo animal models. Whereas progress has been
made in defining human B-lineage developmental popula-
tions9-14 and the consequences of inherited B-lineage genetic
defects,4,15-18 the evolution of human B-lineage culture models
analogous to those established using murine cells19-23 has been
technically challenging.24 Recently, important progress has
been made in sustaining the growth of immature human B
progenitors using primary human bone marrow stroma or using
human or murine stromal cell lines.25-30 As part of these studies
we have developed a stromal cell-dependent culture model that
permits the generation and long-term growth of CD101CD191
human B progenitors derived from either CD341CD381 or
more primitive CD341CD382 multipotent hematopoietic stem
cell progenitors.31-33
An ideal B-lineage culture model should support B-lymphoid
commitment from multipotent input stem cells and both pri-
mary and secondary B-lymphoid development. A major limita-
tion of the human long-term B-progenitor culture system we
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have described and of related murine B-lineage culture systems
has been their limited capacity for expansion of surface Ig1
(sIg1) B cells and the generation of mature B-cell populations.
Some of the key signals controlling mature B-lineage develop-
ment have been modeled in vitro using fibroblast lines express-
ing the CD40 ligand (CD40L; reviewed in Banchereau et
al49).34,35 CD40 activation in association with specific growth
factors has been used to promote mature B-cell survival,
proliferation, and differentiation. These observations suggested
that a B-lineage culture system that combined sequentially the
use of a bone marrow stromal cell line and CD40 activation
signals might overcome some of the limitations of current in
vitro culture models.
We describe here the establishment of a human B-lineage
culture system that supports the major events in both primary
and secondary B-lineage development. This system uses two in
vitro culture stages: generation of pro-B–cell to immature B-cell
populations from multipotent hematopoietic progenitors using
stromal cell support; and polyclonal expansion and maturation
of these immature IgM1IgD1/2 B cells into Ig-producing B cells
after CD40 cross-linking. This system provides a powerful model
for use in a range of future studies of both normal and altered
human B lymphopoiesis, including evaluation of the capacity
for B-lineage development after gene transfer into normal or
immunodeficient hematopoietic stem cells.
MATERIALS AND METHODS
Cell sources, cytokines, antibodies, and flow cytometry. Umbilical
cord blood, obtained according to the guidelines approved by the UCLA
or Childrens Hospital Los Angeles Committees on Clinical Investiga-
tion (IRB), was placed in sterile tubes containing heparin (10 U/mL),
stored at room temperature, and processed within 24 hours. The murine
stromal cell line S17 (kindly provided by Dr K. Dorshkind, University
of California, Los Angeles, CA)36 and murine fibroblasts stably
transfected with a human CD40 ligand (CD40L) cDNA (kindly
provided by Dr J. Banchereau, Schering-Plough, Dardilly, France)37,38
were maintained as previously described. Human recombinant cyto-
kines were used at the following concentrations: interleukin-10 (IL-10;
100 ng/mL) and IL-4 (100 ng/mL) (generous gift from Dr S. Narula,
Schering-Plough, Kenilworth, NJ), Flt3 ligand (FL; 50 U/mL), and IL-2
(100 ng/mL; a gift from Amgen Inc, Thousand Oaks, CA).
Antibodies, including fluorescein isothiocyanate (FITC)- or phyco-
erythrin (PE)-conjugated anti-CD19 (Leu 12), PE-conjugated anti-
CD20 (Leu 19), FITC-conjugated anti-CD10 (Calla), tricolor-conju-
gated anti-CD38 (OKT10), Simultest anti-k/l, FITC-conjugated anti-
major histocompatibility complex (MHC) class II DR (Becton Dickinson
Immunocytometry Systems, San Jose, CA), FITC-or PE-conjugated
anti-IgM F(ab)82, PE-conjugated anti-IgD, and FITC-conjugated anti-
mouse IgM (Southern Biotechnology, Birmingham, AL) were used for
phenotypic studies as recommended by the manufacturers. The biotinyl-
ated anti-VpreB monoclonal antibody (MoAb; MAD688) was used as
previously described.39 Two-color flow cytometry analysis of cultured
cells was performed as previously described,31,32 and all samples were
simultaneously analyzed using isotype control antibodies. For multi-
color staining using indirect staining with the anti-VpreB MoAb, cells
were successively incubated with biotinylated anti-VpreB and spectral-
Red conjugated streptavidin before incubation with other antibodies or
cell permeabilization. For intracellular analysis of µ heavy chains, cells
were permeabilized and fixed by 30 minutes of incubation at room
temperature in Permeafix solution as recommended by the manufacturer
(Ortho Diagnostics Systems, Raritan, NJ). Gating on MAD688-positive
cell populations was determined using analysis with control Ig (or
spectral-Red–conjugated streptavidin) versus anti-k/l or anti-IgM.
Control stains were evaluated using for both cell surface analysis and in
analysis of permeabilized cells using VpreB-positive and -negative
control cell lines and CD191 progenitors. Cell cycle analysis was
determined by measurement of the incorporation of the DNA fluoro-
chrome propidium iodide (32 µmol/L) as described.40
Enrichment of CD341 cord blood cells and establishment of human
B-progenitor long-term cultures (HB-LTC). Low-density mono-
nuclear cells (MNC) from umbilical cord blood were separated by
centrifugation on Ficoll-Hypaque (d 5 1.077; Amersham Pharmacia,
Piscataway, NJ) and CD341 progenitor cells were isolated using the
MACS CD34 Isolation Kit (Miltenyi Biotechnology, Auburn, CA) as
recommended by the manufacturer. Collected adsorbed cells were
typically greater than 95% CD341 by flow cytometry. Highly purified
CD341CD382 cord blood cells were defined strictly as those with high
CD34 expression and anti-CD38 PE fluorescence less than one half of the
maximum PE fluorescence of the isotype control and were isolated by cell
sorting as previously described.32 S17 stromal cells, resuspended in RPMI1640
(Irvine Sciences, Tustin, CA) supplemented with 2 mmol/L glutamine, 50
mmol/L 2-mercaptoethanol, and 3% defined fetal calf serum (Hyclone
Laboratories, Logan, UT) were plated in tissue culture plates (Falcon; Becton
Dickinson Labware, Franklin Lakes, NJ) to obtain 50% confluent mono-
layers within 24 to 48 hours. Cord blood stem cell progenitors were
plated on the 50% to 60% confluent S17 monolayers as previously
described.31,32 Briefly, CD341 enriched cells were plated at a density of
0.5 to 2 3 106 cells per 10-cm dish and sorted CD341CD382 cells were
plated at a density of 0.5 to 5 3 103 cells/well. Cultures were fed
biweekly, once with the addition of fresh medium and once by aspiration of
80% of the medium in the culture well and addition of fresh medium.
Some cultures were supplemented with recombinant soluble FL at a
final concentration of 50 U/mL as described previously.32
Separation of the CD191 cells from long-term S17 culture and
culture on CD40L fibroblasts. Long-term cultured cells were har-
vested with or without the adherent cell monolayer and passed through a
40-µm nylon cell strainer (Falcon). Dead cells and debris (mostly from
the S17 monolayer) were removed by centrifugation of the single-cell
suspension over a Ficoll-Hypaque cushion and CD191 B cells were
isolated by using the MiniMacs cell separation system as recommended
by the manufacturer (Miltenyi Biotech). Briefly, cells were incubated
with a anti-CD19 antibody coupled to super-paramagnetic beads before
being passed through a positive selection column (MACS column, or
MACS MS when stromal cells were harvested in association with
hematopoietic cells). Collected adsorbed cells were used for staining
and/or for secondary cultures. Secondary cultures were prepared using
either a newly plated 60% confluent S17 monolayer or CD40L
fibroblasts as previously described.37,38,41 CD40L fibroblasts were
irradiated with 8,000 rad before plating in 96- or 48-well plates at 5 3
103 or 2 3 104 cells/well, respectively. CD191 cells were added to
CD40L fibroblasts (0.05 to 5 3 105 cells/well) with cytokines as
indicated in Results. CD191 cells were transferred to freshly irradiated
CD40L fibroblasts every 5 to 7 days for the duration of the experiments
described.
Ig secretion assay. Purified CD191 cells were seeded on CD40L L
cells at 5 3 105 cells/mL (or at other cell densities as noted) in 96-well
plates in a final volume of 100 µL with the indicated cytokines. At days
8 and 15, cells were transferred to freshly irradiated CD40L fibroblasts
with fresh cytokines (final volume, 200 µL) and cultured for an
additional 7-day period. Culture supernatant (180 µL) was collected at
day 7, 14, or 21; spun to remove cell debris; and frozen for further
analysis. Enzyme-linked immunoabsorbtion assay (ELISA) for IgM
production was performed in microtiter plates coated overnight with
1/5,000 dilution of goat antihuman IgM (µ specific; Southern Biotech-
nology) in carbonate buffer. Plates were incubated with samples or
standards (human Ig standard; ICN Pharmaceuticals, Aurora, OH) for 4
hours at 4°C and bound antibody was detected using an alkaline
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phosphatase-conjugated rabbit antihuman IgM (1:5,000 dilution; Jack-
son Laboratories, West Grove, PA) followed by p-nitrophenyl phos-
phate as substrate. Plates were scanned at 409 nm in a multiwell reader
(Molecular Devices, Sunnyvale, CA) and analyzed using Soft Max
software (Molecular Devices). For IgG determinations, goat antihuman
IgG (1:5,000 dilution; Southern Biotechnology) was used as capture
antibody, followed by detection using biotinylated goat antihuman Ig (H
1L chains; 1:5,000 dilution; Southern Biotechnology), streptavidin-
alkaline phosphatase (1:1,000 dilution; Sigma, St Louis, MO), and
substrate. Limits of detection were 2 ng/mL (IgM) and 0.5 ng/mL (IgG).
Results are presented as the average of $3 determinations. The co-
efficient of variation between samples was always less than 10%. Notably,
the addition of 50 µmol/L 2-mercaptoethanol supported cell survival
and was associated with an approximately threefold to fivefold increase
in detectable Ig in cultures established with HB-LTC CD191 progenitors.
cDNA preparation and polymerase chain reaction (PCR). Cells
were collected and RNA extracted using RNAzol (Biotecx, Houston,
TX) or, alternatively, limited numbers of fluorescence-activated cell
sorting (FACS)-sorted cells (103, 102, 101, or single cells) were
resuspended in 5 µL of phosphate-buffered saline (PBS). Samples were
heated for 2 minutes at 65°C and then chilled on ice before the addition
of the reverse transcriptase (RT) reaction mix (Superscript GIBCO;
GIBCO, Grand Island, NY; Ghia et al12). The RT reaction was
performed by incubation for 1 hour at 37°C, followed by inactivation of
the enzyme for 10 minutes at 95°C. RT-PCR amplification of VpreB, µ,
CD79b (B29), k light chain, terminal deoxynucleotidyl transferase
(TdT), and recombination associated gene (Rag) transcripts were
performed in one or two rounds using primer pairs specific for VpreB, µ,
CD79b, k, TdT, Rag 1, and G3PDH (complete primer sequences
available from D.J.R. upon request).
RT-PCR amplification of VH families was performed using primers
described previously.42 After two rounds of PCR, products of the
expected size were evaluated by ethidium bromide staining after
separation by agarose gel electrophoresis. Comparison of the reaction
products using decreasing numbers of input CD191 cells (103, 102, and
101 cells, respectively) were used to semiquantitatively evaluate the
relative expression of the individual VH families. The limits for the
detection of VH messages by ethidium staining was 100 to 1,000 cells
from HB-LTC and 10 to 100 cells from CD40L cultures. This was
consistent with the expansion of IgM1 B cells in the CD40L system.
Each PCR reaction consisted of denaturation cycle at 94°C for 2
minutes, followed by 30 cycles each of 94°C for 30 seconds, 55°C for
40 seconds, 72°C for 60 seconds, and a final extension cycle at 72°C for
7 minutes. The reaction mix for the first round PCR included all the VH
family primers. Second-round PCR was performed using individual
primer pairs and 1 µL of the first-round product.
RESULTS
Multiple early B-lineage transcripts are detectable in HB-
LTCs. Long-term culture of human cord blood CD341 input
cells on the S17 murine bone marrow stromal cell line results in
the emergence of a highly enriched population of CD342CD191-
CD101 B-lineage progenitors (HB-LTC).31,32 In the current
study, we sought to determine if these cultures supported
B-lineage subpopulations representative of those present in vivo
in normal human bone marrow and, if so, whether these popula-
tions retained the capacity for mature B-lineage development.
HB-LTC progenitors were first evaluated for the expression
of key developmentally regulated B-lineage–specific tran-
scripts, including TdT, the recombination-activating genes
(Rag-1 and -2), surrogate light chain (VpreB), µ heavy chain,
and k or l light chains. Analysis of the expression pattern of
these transcripts and their protein products has previously been
used to order the pro-B–cell to immature B-cell developmental
sequence in normal human bone marrow.12 CD191 B-
progenitor cells were collected from long-term cultures at 8
weeks for RNA extraction and RT-PCR analysis. Messages for
TdT and Rag-1 and -2 (Fig 1) were clearly detected, consistent
Fig 1. B progenitors from HB-LTC express mRNA for TdT, Rag,
VpreB, m, and light chain. RT-PCR was performed using the primer
pairs as described in Materials and Methods with (lane 1) RNA from
nonadherent cells of 8-week-old HB-LTC; (lane 2) RNA from S17 cells
grown in the same conditions without addition of the CD341 progeni-
tors; (lane 3) no added RNA; (N) RNA from the human pre-B–cell line,
Nalm-6; or (R) RNA from the human IgM1 immature B-cell line,
Ramos. Lane M contains DNA size standards. Results are representa-
tive of at least three independent experiments using unrelated
HB-LTCs.
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with their expression by an early B-progenitor population.
Transcripts encoding VpreB, µ heavy chain, and k or l light
chains were also detectable by RT-PCR analysis (Fig 1). The
results obtained evaluating bulk CD191 populations were
confirmed by additional analysis of FACS-purified HB-LTC
subpopulations (data not shown). Together, these results sug-
gested that HB-LTC might support several distinct B-lineage
developmental subpopulations, including early TdT1 B progeni-
tors, VpreB1 cells, and, possibly, IgM1 immature B cells.
HB-LTC supports the expansion of human pro-B cells, pre-B
cells, and immature IgM1 B cells. To further characterize the
B-progenitor subsets in HB-LTC, nonadherent cells from mul-
tiple 4- to 10-week-old cultures were analyzed by flow cytome-
try for expression of CD19 with either the VpreB surrogate light
chain or intracytoplasmic or surface Ig µ chains (cµ and IgM;
Fig 2). The MoAb, MAD688, recognizes both VpreB1cµ2 and
VpreB1cµ1 B progenitors and has been used to characterize
these populations in human cell lines and bone marrow.12,39
VpreB expression was detected as early as 4 weeks in HB-LTC,
and 5% to 15% of the CD191 cells expressed VpreB by 6 to 8
weeks (Fig 2A).
Rearrangement of the µ heavy chain locus leads initially to
intracytoplasmic expression of µ in early B-cell precursors.
Expression of cµ was found in 8% to 18% of the CD191 cells
(Fig 2A). Successful rearrangements of the k or l light chain
genes in cµ1 cells leads to surface IgM expression. IgM
expression was detected in 3% to 10% of the CD191CD101
progenitors (3% in Fig 2A). Double staining demonstrated
coexpression of either k or l light chains with surface IgM (data
not shown). The CD191 cells expressing either k or l light
chain did not react with the anti-VpreB antibody (Fig 2B).
Notably, approximately 60% of the IgM1 cells also coexpressed
IgD (Fig 2C). Overall, the frequency of VpreB1, cµ1, and IgM1
progenitor cells varied relatively little between cultures or
within individual cultures during weeks 6 through 8. In six
independent cultures, an average of 6% (62%) VpreB1 cells,
10% (62.5%) cµ1 cells, and 3.3% (60.9%) sµ1 cells were
detected.
We used three-color FACS analysis for VpreB, cµ, and
surface IgM chain expression to further delineate the CD191
subpopulations from several HB-LTCs. Analysis of purified
CD191 progenitors (.95% CD191) confirmed the presence of
several distinct B-lineage subpopulations, including a predomi-
nant population of VpreB2Cµ2IgM2 cells (74% in this ex-
ample; Fig 2D and data not shown); smaller numbers of VpreB1
cells consisting of VpreB1Cµ2IgM2 and VpreB1Cµ1IgM2
subsets (18%); and a limited number of both VpreB2Cµ1IgM2
and VpreB2Cµ1IgM1 cells (8%).
Fig 2. Multiple B-progenitor
cell subsets are represented in
HB-LTC. Nonadherent cells from
HB-LTC were collected at 6 to 8
weeks for FACS analysis. (A)
Two-color analysis demonstrat-
ing the presence of HB-LTC
CD191 progenitors expressing
surrogate light chain (VpreB), cy-
toplasmic m (Cm), or surface IgM.
(B) Analysis demonstrating inde-
pendent expression k versus l
light chains and of VpreB versus
k or l light chain. (C) Analysis
demonstrating coexpression of
IgM and IgD within HB-LTC im-
mature IgM1 B-cell population.
(D) Example of three-color analy-
sis of purified HB-LTC CD191
progenitors showing staining of
VpreB versus cm. This analysis
showed VpreB2cm2IgM2 (R1)
progenitors; VpreB1cm2IgM2
(R2) and VpreB1cm1IgM2 (R3)
subsets; and VpreB2cm1IgM2
and VpreB2cm1IgM1 subsets (R4;
IgM data not shown). Results
are representative from more
than eight independent experi-
ments. Numbers indicate the
percentage of cells in each quad-
rant.
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Because pre-B cells comprise the major cycling population in
murine and human bone marrow,12,43 we evaluated the relative
size and cell cycle status of the VpreB1 progenitors present in
HB-LTCs. Analysis according to cell size showed that the
VpreB1 population consisted predominantly of larger cells (Fig
3A, R2 gate), whereas the VpreB2IgM2 and IgM1 populations
were composed of very small cells (R1 gate). In addition,
analysis of DNA content indicated that the VpreB1 cells
contained the majority of CD191 cells in cell cycle (25% of
VpreB1 were in S/G2/M v 2 % for VpreB2 cell population; Fig
3B).
Together, these results demonstrate that HB-LTC results in
the expansion of multiple stages of early B-cell development,
including a majority population of pro-B cells (CD191-
VpreB2Cµ2IgM2); large, cycling pre-B cells (VpreB1Cµ2IgM2
and VpreB1Cµ1IgM2 cells); and a limited number of relatively
quiescent, immature B cells (VpreB2Cµ1IgM1IgD1/2). The
multiparameter analysis described above also suggested the
presence of transitional subpopulations within these major
developmental stages. As previously reported, CD341 pro-B
cells were not detected in HB-LTC.31
The continuum of B-lineage differentiation in HB-LTC stops
at the stage of immature IgM1 B cells. IgM1 cells were
undetectable by FACS analysis before 5 weeks of culture on
S17 stroma. The relative frequency of IgM1 cells increased
slowly beginning at 5 weeks and reached a maximum of 3% to
10% between weeks 6 and 8. Extended culture for up to 12
weeks resulted in no significant further increase in the fraction
of IgM1 B cells (data not shown). Consistent with these
observations, analysis of cell size and cell cycle demonstrated
that the k- or l-expressing cells were predominantly within the
smaller, quiescent CD191 population (data not shown). Nota-
bly, all the HB-LTC–derived CD191 cells, including the IgM1,
IgD1 population, coexpressed both CD10 and CD38 (data not
shown and Fig 4C). This phenotype contrasts with that of
circulating naive human peripheral B cells, which are predomi-
nantly composed of IgM1IgD1CD102CD382 cells. Together,
this relatively immature surface phenotype and the limited
expansion of IgM1 cells suggested that the S17 stromal line was
unable to provide the appropriate developmental signals re-
quired for the expansion and subsequent maturation of the
IgM1 immature B cells generated in these HB-LTCs.
CD40 ligand stimulation promotes the expansion and matura-
tion of long-term cultured IgM1 B cells. Analysis of HB-LTC–
derived CD191 progenitors clearly demonstrated cell surface
expression of CD40 (data not shown). Both fetal BM-derived
CD341CD192 and CD191IgM1/2 progenitors express CD40
and proliferate in response to CD40 activation.44-46 CD40
activation is also critical for activation and proliferation of
mature human B cells.47-49 We therefore evaluated whether a
combination of CD40L activation in association with cytokines
would promote the expansion and/or the maturation of HB-LTC
B progenitors. CD191 cells were isolated from 8-week-old
cultures and transferred onto either irradiated mouse fibroblasts
stably expressing human CD40L37,38 or to fresh S17 stroma,
each in the presence of IL-4 and IL-10 (100 ng/mL). Strikingly,
Fig 3. The HB-LTC CD191 VpreB1 population is composed of predominantly large, cycling cells. B-lineage cells were separated from 8-week-old
HB-LTC by positive selection using anti-CD19 magnetic beads and stained with anti-VpreB and anti-IgM antibodies and analyzed by flow
cytometry. (A) (Left) Forward and side scatter analysis of total cell population showing gated R1 (smallest) or R2 (largest) cell populations. (Right)
VpreB1 and VpreB2 populations in gates R1 or R2, with numbers indicating the percentages of the total CD191 cell population in each quadrant.
(B) Cell cycle analysis of CD191VpreB1 cells. CD191 were stained with the anti-VpreB antibody before permeabilization and staining with propidium
iodide for FACS analysis of DNA content versus surface VpreB expression (R3 5 VpreB2 and R4 5 VpreB1 populations, respectively). Numbers
indicate the relative percentage of cells in S/G2/M.
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large, loose aggregates of activated blast-like CD191 cells in
close association with the CD40L fibroblasts were evident
within 5 to 8 days after cell transfer. The majority of these
CD191 cells exhibited eccentric nuclei, a low nuclear to
cytoplasmic ratio, and increased mitotic figures (Fig 4A).
Within 14 days of culture on CD40L fibroblasts, a predominant
population of large plasmacytoid cells were present. In contrast,
cells transferred to S17 with or without cytokines contained
only small lymphoid cells, with a high nuclear to cytoplasmic
ratio without evidence of cellular activation.
FACS analysis showed significant alterations in the surface
phenotype of the CD40L-cultured B cells (Fig 4B and C). In
seven independent cultures established with cord blood progeni-
tors, the frequency IgM1 B cells increased to an average of
greater than fourfold within 7 to 14 days. This included an
increase in the frequency of both IgM1IgD2 and IgM1IgD1 B
cells. In the representative experiment presented in Fig 4C, the
total IgM1 population increased from 4% to 12% and the
IgM1IgD1 population increased from 2% to 9%, respectively.
IgM2 and naive IgM1 B cells upregulate CD23 expression, and
naive B cells also downmodulate CD10 and CD38 expression in
response to CD40 cross-linking.45,49-51 The majority of HB-LTC–
derived CD191 cells, including all the IgM1 cells, acquired
CD23 expression after culture with CD40L fibroblasts. CD10
and CD38 expression also decreased significantly in both the
IgD2 and IgD1 populations (Fig 4C). In contrast, CD191 cells
transferred onto S17 with IL-4 and IL-10 showed no alteration
in phenotype, with the exception of a slight increase in CD23
expression.
We also determined the proliferative capacity of HB-LTC–
derived CD191 cells after transfer to the CD40L system.
CD191 cells isolated from 8-week-old HB-LTCs were cultured
with CD40L or S17 stroma with or without added cytokines
(Fig 5A). Whereas culture on CD40L fibroblasts without added
Fig 4. CD40 ligand stimula-
tion promotes the expansion and
maturation of long-term cultured
IgM1 B cells. Purified CD191 pro-
genitors from 8-week-old HB-
LTC were transferred onto
freshly plated S17 stroma or
onto irradiated CD40L fibroblasts
in medium supplemented by IL-4
and IL-10 and collected after 8
days in culture. (A) Wright-Gi-
emsa staining of CD191 cells
(original magnification 3 1,000)
demonstrating plamacytoid ap-
peareance of CD191 cells in the
CD40L system. (B) (Upper panel)
FACS analysis demonstrating in-
crease in IgM1 B cells after trans-
fer to the CD40L system. (Lower
panel) Results of anti-IgM stain-
ing after transfer to S17 versus
the CD40L system using CD191
cells from 7 independent HB-
LTCs. (C) FACS analysis demon-
strating the increase in IgM1,
IgM1IgD1 populations, the in-
crease in CD23 expression, and
the decrease CD10 and CD38 ex-
pression in CD191 progenitors
after transfer to the CD40L sys-
tem.
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cytokines maintained input CD191 cell numbers, the addition
of IL-4 increased cell recovery fivefold. IL-10 had no signifi-
cant effect on total cell recovery. The addition of IL-4 and/or
IL-10 to S17 stromal culture did not appreciably affect viable
cell recovery. Analysis of thymidine incorporation in CD191
cells under these culture conditions yielded similar results (data
not shown).
Consistent with these observations, the combination of CD40
activation and IL-4 supported entry of the B-lineage cells into
cell cycle. By day 8, 15% to 35% of cells under these conditions
were in S/G2/M phase (,25% in the experiment shown in Fig
5B). Double staining for surface IgM and DNA content
indicated that both the IgM2 and IgM1 CD191 progenitors
were in cell cycle at this time point (with 21% and 23% of cells
in cycle, respectively). By transferring the cells weekly onto
newly irradiated fibroblasts with IL-4 and IL-10, CD191 cell
expansion could be maintained for more than 4 weeks.
HB-LTC–derived IgM1 B cells secrete Ig and undergo
isotype switch in response to CD40 cross-linking and cytokines.
Although our data indicated that both the IgM2 and IgM1
HB-LTC populations proliferated and modulated their surface
phenotype in response to CD40 activation, it remained unclear
if these populations had the capacity for more mature B-lineage
functions, including Ig secretion. We therefore evaluated if
culture in the CD40L system lead to Ig secretion. Table 1 shows
a representative experiment in which CD191 cells isolated from
a 6-week-old HB-LTC were transferred to CD40L fibroblasts
with cytokines including IL-2, IL-4, and/or IL-10. Strikingly,
IgM production was detected by ELISA within 7 to 14 days in
supernatants of cultures supplemented with both IL-4 and
IL-10. Secretion of IgM was detected using CD191 progenitors
derived from 6 of 6 independent HB-LTCs cultures after
transfer onto CD40L-expressing fibroblasts supplemented with
both IL-4 and IL-10 (data not shown). IgM production peaked
Fig 5. CD40L culture enhances the proliferation
of HB-LTC–derived CD191 progenitors. A representa-
tive experiment in which CD191 progenitors from an
8-week-old HB-LTC were seeded in microwells (105
cells/well) containing S17 stromal cells or CD40L
fibroblasts in medium containing no added cyto-
kines, IL-4, IL-10, or both cytokines. (A) Cell recovery
was determined by trypan blue dye exclusion and
expressed as the mean number of viable cells. (B)
Cell cycle analysis of CD191 cells removed from the
CD40L system. (Left) Dot plot of IgM versus DNA
content analyzed by propidium iodide staining.
(Right) Histogram illustrating DNA content in the
IgM1 (R1) versus the IgM2 (R2) populations. Num-
bers indicate the percentage of cells in S/G2/M.
IN VITRO RECONSTITUTION OF B-CELL ONTOGENY 4515
For personal use only.on June 4, 2016. by guest  www.bloodjournal.orgFrom 
after 21 days and subsequently decreased (Table 1 and data not
shown). Using limiting dilution, IgM production (2 to 5 ng/mL)
was readily detectable with as few as 103 of CD191 input cells.
More limited IgM secretion was also detected in cultures
supplemented with only IL-4, with only IL-10, or with both
IL-2 and IL-10.
Engagement of CD40 on naive B cells activates signals
required for Ig isotype switching and this response is modulated
by specific cytokines.49 We evaluated whether culture of
HB-LTC CD191 cells in the CD40L system could support the
events leading to IgG secretion by this cell population (Table 1).
Soluble IgG was clearly detected in supernatants from cells
cultured in IL-4 and IL-10 after 14 days. IgG secretion was
significantly less than the production of IgM (9.7 v 111 ng/mL).
IgG production increased eightfold by day 21 and the relative
amount of IgG versus IgM also increased (78 v 176 ng/mL).
Limited IgG production (,10-fold less than in cultures contain-
ing both cytokines) was also detected using either IL-4 or IL-10
alone.
The concentration of IgM produced in the CD40L system
correlated with the relative percentage of IgM1 cells in the input
cell population (data not shown). To determine the CD191
population responsible for the majority of Ig production,
identical numbers of FACS sorted CD191IgD2 and more
mature CD191IgM1IgD1 cells from a 7-week-old culture were
cultured in the CD40L system. Cell expansion was equivalent
for both populations. A small subpopulation of IgM1 IgD1 cells
(5%) was detectable within 8 days in cultures initiated with
IgD2 cells (data not shown). However, only cultures initiated
with the IgD1 cells produced significant amounts of soluble
IgM within that time period (.300 ng/mL; data not shown).
These data support the conclusion that expansion and differen-
tiation of the IgM1 B-cell subpopulation from HB-LTCs is
responsible for the majority of Ig production after transfer to the
CD40L system.
HB-LTC B progenitors exhibit polyclonal VH family gene
usage before and after transfer to the CD40L system. The cell
expansion observed in the HB-LTC or the CD40L stages of this
culture model could have resulted from either expansion of a
limited number of independent B-cell clones with a high
proliferative capacity or by expansion of multiple independent
clones. To broadly distinguish between these possibilities, we
evaluated whether the emergence of IgM1 B cells in HB-LTC
and/or the subsequent expansion of these cells after transfer to
the CD40L system was associated with the presence of oligoclo-
nal B-cell populations. VH family gene usage in CD191 cells
from 8-week-old HB-LTC was determined by RT-PCR analysis
using primers specific for the six major human VH families (VH1
to VH6).42 A portion of the CD191 cells from each HB-LTC
were also transferred in CD40L fibroblasts with IL-4 and IL-10
and reevaluated by RT-PCR after 8 days in culture (Table 2).
VH transcripts for all six families (with predominant use of
the VH1, VH3, VH4, and VH6 families) were detected in HB-LTC
B progenitors from five independent cultures (Table 2). Transfer
of these same HB-LTC CD191 populations onto CD40L
fibroblasts with IL-4 and IL-10 (and the associated proliferation
of IgM1 B cells) did not significantly alter the relative pattern of
VH gene family usage. Thus, rather than supporting the out-
growth of a limited subset of oligoclonal B-lineage progenitors,
these data strongly suggest that the HB-LTC system and culture
of HB-LTC–derived B progenitors on CD40L support the
expansion and subsequent activation of polyclonal B-cell
populations expressing a diverse repertoire of VH family genes.
Generation of Ig-secreting IgM1 B cells from highly purified
CD341CD382 hematopoietic stem cells. We evaluated whether
HB-LTCs initiated with a highly enriched hematopoietic stem
cell population (composed of CD341CD382 cells) were also
capable of generating IgM1 B cells and, if so, whether these
cells could differentiate in the CD40L system. A small subpopu-
lation of IgM1 cells coexpressing either l or k light chains were
detectable by 12 weeks in cultures initiated with highly purified
CD341CD382 cord blood cells (Fig 6A). The generation IgM1
cells was relatively delayed in cultures initiated with
CD341CD382 cells compared with cultures containing
CD341CD381 input cells (10 to 12 weeks v 5 to 6 weeks).
These findings were consistent with our previous studies
demonstrating delayed expansion of this relatively quiescent
population in long-term cultures.32,52 As previously reported for
CD191 B-progenitor outgrowth,32,53 addition of FL throughout
Table 1. CD40L Culture Supports Differentiation of the
HB-LTC–Derived CD191 Cells Into IgM-Producing B Cells




Day 14 Day 21
IgM IgG IgM IgG
CD341
Medium ,0.5 ,0.1 0.9 ,0.1
IL-2 ,0.5 ,0.1 0.6 0.3
IL-4 5.0 0.2 54 7.3
IL-10 14 0.9 22 8.1
IL-2/IL-10 66 0.8 60 0.8
IL-4/IL-10 111 9.7 176 78
CD341CD382
IL-4/IL-10 3.5 6 2.2 23.1 6 2.8 ND ND
Representative experiment evaluating the time course of IgM
production after transfer of HB-LTC CD191 cells onto CD40L fibro-
blasts under alternative cytokine conditions. Secretion of IgM and IgG
derived from CD341CD381 (top, 1 3 105 input CD191 cells) and
CD341CD382 progenitors (bottom, 5 3 103 input CD191 cells).
Abbreviation: ND, not determined.
Table 2. HB-LTC B Progenitors Exhibit Polyclonal VH Family Gene
Usage Before and After Transfer to the CD40L System
VH
Family











VH1 111 111 1 11 1/2 1
VH2 1 1 1/2 11 2 2
VH3 11 11 1 1 2 1
VH4 11 1 1 1 2 1/2
VH5 1 2 2 2 2 2
VH 6 11 11 11 1 11 2
Semiquantitative PCR results of a representative experiment using
decreasing numbers of CD191 input cells before and after transfer
onto CD40L fibroblasts are shown. VH family gene usage was deter-
mined by RT-PCR analysis as described in Materials and Methods.
Results shown are representative of three independent experiments
using unrelated HB-LTCs.
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the culture period increased the total production of B-lineage
progenitors, including immature IgM1 B cells (data not shown).
CD191 B progenitors from HB-LTC initiated with
CD341CD382 were isolated by FACS sorting and transferred
onto CD40L fibroblasts with IL-4 and IL-10 (5 3 103 cells/
well). After 15 days, culture supernatants were evaluated by
ELISA for the presence of Ig. Replicate wells containing
CD191 cells from three independent CD341CD382 cord blood
cultures contained 3 to 6 ng/mL of IgM (Fig 6B). This level of
IgM production was comparable to the levels produced using
identical numbers of CD191 cells isolated from cultures
initiated with CD341CD381 progenitors. Notably, IgG produc-
tion was also clearly detectable in cultures initiated with
CD341CD382 cells (20 to 25 ng/mL; Table 1). Interestingly, in
this limited set of experiments, the relative production of IgG
versus IgM was significantly higher than in cultures initiated
with CD341CD381 input cells. Together, these observations
strongly support the conclusion that this culture model supports
both the events regulating commitment of hematopoietic stem
cells to B-lymphoid development and the sequential B-lineage
developmental events culminating in production of mature
Ig-secreting B cells.
DISCUSSION
The culture system described in this work meets several key
criteria of an optimal in vitro human B-lineage developmental
model (Fig 7). First, this model supports the growth of
B-lineage progenitor populations with cell surface phenotypes
consistent with most of the major B-lineage developmental
subpopulations present in normal human bone marrow, includ-
ing pro-B cells, cycling pre-B cells, and IgM1 IgD1/2 immature
and naive B cells. Notably, because the signals generated by the
human pre-BCR remain very poorly defined, the capacity for
this culture model to support a cycling pre-B–cell population
may facilitate future studies regarding this receptor system.
Most notably, activation of these long-term cultured CD191
progenitors by CD40 cross-linking lead to mature B-lineage
developmental events, including Ig production and isotype
switching. Determination of the expression pattern of develop-
mentally regulated B-lineage gene products (including VDJ
gene rearrangement status, Rag and TdT expression, and mature
B-lineage marker expression) within individual FACS-sorted
cells is essential to fully characterize these populations. How-
ever, the demonstration of mature B-lineage function strongly
Fig 6. HB-LTCs initiated with
CD341CD382 stem cells lead to
production of IgM1 B cells ca-
pable of secreting of Ig after
transfer to the CD40L system.
HB-LTCs were established in
microwells using FACS-sorted
CD341CD382 cord blood cells.
(A) Total cultured cell popula-
tions (adherent and nonadher-
ent cells) from independent wells
were collected at weeks 12 and
13 and evaluated by FACS after
gating on the lymphoid-sized
population. (B) Decreasing num-
bers CD191 cells from cultures
initiated with either CD341CD381
(0.125 to 2 3 104 CD191 cells/
well) or CD341CD382 input cells
(5 3 103 CD191 CD191 cells/well;
4 independent wells shown)
were transferred to CD40L sys-
tem with IL-4 and IL-10. Produc-
tion of IgM was evaluated by
ELISA after 14 days. Results
shown are representative of
three independent experiments.
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supports the conclusion that this model represents a physiologi-
cally relevant continuum of human B lymphopoiesis.
Second, this model supports both the commitment of multipo-
tent stem cells to B-lineage development and the progression of
these committed progenitors into functionally mature B cells.
This conclusion is supported by analysis of HB-LTCs initiated
with highly purified CD341CD382 cells, a rare, quiescent,
primitive progenitor cell population capable of myeloid, B- and
T-lymphoid, erythroid, and megakaryocitic differentia-
tion.30,32,33,54-56 The mature B cells generated in these cultures
are very unlikely to be derived from contaminating IgM1 input
cells for several reasons, including the lack of CD19 expression
in the purified CD341CD382 input population32; the demon-
strated capacity of single CD341CD382 cells to generate both
myeloid and B-lymphoid progenitors in S17 stroma-supported
culture33; the delayed kinetic of CD191IgM1/2 cell outgrowth;
and the inability of S17 stromal cultures to support long-term
expansion of isolated cord blood IgM1 B cells (Fluckiger and
Rawlings; unpublished data).
Third, a key objective of in vitro culture models is that they
support efficient expansion of polyclonal cell populations
representative of those present in vivo. Analysis of the reper-
toire of Ig VH gene expression demonstrated that this model
supports expansion and activation of multiple independent
B-lineage clones. In addition, B-lineage subpopulations are
reproducibly generated in sufficient numbers for relatively
extensive phenotypic, molecular, biochemical, and/or func-
tional analyses. For example, a typical 6-week-old culture
established using CD341 progenitors yielded approximately
1 3 108 CD191 progenitors (including 0.5 to 1 3 106
CD191IgM1 B cells) and sustained this production level for
several weeks.
Fourth, several groups have used SCID/Hu and related in
vivo models to maintain either immature human B progenitors
derived from multipotent hematopoietic progenitors or mature
IgM1 B cells.57-60 However, the continuum of human B
lymphopoiesis present in the culture model described in this
work has not yet been possible with SCID/Hu systems. This in
vitro model uses two well-characterized cell lines, recombinant
cytokines, and has been established with a relatively broad
group of serum sources. It should therefore be reproducible in
many laboratories. These features are likely to permit studies
that are not readily achievable using a more complex SCID/Hu
system.
The most significant development described in this work is
the combination of HB-LTC with signals leading to mature
B-lineage development. This study and previous studies have
suggested that bone marrow stroma-supported cultures do not
provide the signals required for maturation of IgM1 immature B
cells.29,61,62 We demonstrate that a combination of CD40
activation in association with IL-4 and IL-10 is sufficient to
promote the expansion and maturation of CD191 progenitors
derived from multipotent postfetal hematopoietic progenitors.
These signals lead to modulation of cell surface receptor
expression, polyclonal expansion of IgM1 B cells (including
generation of IgM1IgD1 cells from IgM1IgD2 cells), Ig
production, and Ig isotype switching. The HB-LTC–derived
IgM1IgD1/2 B cells were responsible for the vast majority of Ig
production under these culture conditions. Transfer to CD40L
fibroblasts also led to expansion of the CD191IgM2 population
and supported limited differentiation of this population into
IgM1IgD1 cells. Our observations are consistent with previous
work demonstrating that short-term culture with an activated
CD41 T-cell line and IL-4 led to generation of Ig-producing B
cells from human fetal bone marrow-derived pre-B cells.63 The
activated T-cell line could be replaced using a membrane
preparation from the same cells. Our data suggest that the key
costimulatory signal in those studies was also most likely
provided by CD40L.
Culture of HB-LTC CD191 cells in the CD40L system leads
to generation of a population of CD191CD10dim/2CD38dim/
2IgM1IgD1/2 B cells phenotypically similar to naive tonsillar
B cells. The response of these cells in the CD40L system also
closely paralleled the response of naive B cells under similar
conditions.49 Both HB-LTC CD191 cells and naive B cells
proliferated in response to IL-4 and secreted significant amounts
of IgM and IgG with the addition of IL-10.41,47,48 The addition
of IL-10 also resulted in generation of activated B cells with
Fig 7. In vitro culture model of human B lymphopoiesis. B-lineage developmental subpopulations supported by the two-stage culture
system: HB-LTC followed transfer to CD40L fibroblasts. (Bottom) Bars approximate the relative cell expansion of the subpopulations supported
in each culture stage.
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plamacytoid cell morphology from HB-LTC–derived CD191
cells, as previously reported using naive B cells.64 Finally,
adjusting for relative numbers of IgM1IgD1/2 B cells,
HB-LTC–derived B cells secreted similar amounts of total IgM
as naive B cells in response to IL-10 and IL-4 in the presence of
CD40 cross-linking (,0.05 to 0.1 ng secreted IgM per IgM1
input cell). Together, these observations indicate that the
HB-LTC–derived immature B-cell population functions analo-
gously to in vivo postnatally derived naive B cells, further
supporting the conclusion that this model reproduces key events
in mature B-cell development.
In summary, this culture system provides a unique model for
the study and genetic manipulation of the major transition
points in human B ontogeny. Because this model uses postfetal
tissues (including both cord blood and bone marrow), it should
also facilitate future analyses using hematopoietic tissues
derived from individuals with disorders leading to altered B
lymphopoiesis as well as normal individuals. Use of this model
should allow experiments not previously possible with other
human cell culture systems, including, eg, the in vitro analysis
of the B-lineage developmental consequences of oncogenic
protein expression and the mechanisms regulating the B-cell
antigen receptor repertoire. Finally, optimization of this model
should ultimately permit the generation of Ig-producing B cells
from single multipotent hematopoietic progenitors.
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